We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

100 hedge funds and large institutions have $81M invested in Invesco Biotechnology & Genome ETF in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.2% less ownership

Funds ownership: 34.08% → 32.88% (-1.2%)

7% less funds holding

Funds holding: 108 → 100 (-8)

8% less capital invested

Capital invested by funds: $88.2M → $81M (-$7.25M)

17% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 29

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

Holders
100
Holders Change
-8
Holders Change %
-7.41%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
24
Reduced
29
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$987K
2
BEI
Benjamin Edwards Inc
Missouri
+$840K
3
Citadel Advisors
Citadel Advisors
Florida
+$693K
4
SF
Summit Financial
New Jersey
+$266K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$226K

Top Sellers

1
QAM
Q3 Asset Management
Michigan
-$1.43M
2
IWM
IHT Wealth Management
Illinois
-$1.22M
3
LPL Financial
LPL Financial
California
-$854K
4
Two Sigma Investments
Two Sigma Investments
New York
-$739K
5
GKWIM
Gerber Kawasaki Wealth & Investment Management
California
-$620K
Name Holding Trade Value Shares
Change 		Change in
Stake
HNB
101
Huntington National Bank
Ohio
$79 – – –
QAM
102
Q3 Asset Management
Michigan
– -$1.43M -17,429 Closed
IWM
103
IHT Wealth Management
Illinois
– -$1.22M -14,814 Closed
Two Sigma Investments
104
Two Sigma Investments
New York
– -$739K -9,000 Closed
AWM
105
Axxcess Wealth Management
California
– -$388K -4,725 Closed
Wealth Enhancement Advisory Services
106
Wealth Enhancement Advisory Services
Minnesota
– -$383K -4,562 Closed
Cambridge Investment Research Advisors
107
Cambridge Investment Research Advisors
Iowa
– -$212K -2,583 Closed
MML Investors Services
108
MML Investors Services
Massachusetts
– -$205K -2,497 Closed
BCV
109
Banque Cantonale Vaudoise
Switzerland
– -$44K -530 Closed
CTA
110
Colonial Trust Advisors
South Carolina
– -$25K -304 Closed
WA
111
Waverly Advisors
Alabama
– -$23.2K -282 Closed
CPG
112
Cornerstone Planning Group
New Jersey
– -$13.7K -166 Closed
PA
113
Parallel Advisors
California
– -$1.66K -20 Closed
1 2 3 4
5

PBE Hedge Fund Activity: Q1 2026 in Review

100 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2026, worth a combined $81M — down 8.2% from $88.2M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of PBE and 8 opened new positions — a net loss of 4 holders — while 29 trimmed existing stakes and 24 added.

The largest buyer was Royal Bank of Canada, adding an estimated $987K. The largest seller was Q3 Asset Management, exiting entirely with an estimated $1.43M sold.

  • 100 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2026, down from 108 in Q4 2025.
  • Funds reported $81M of Invesco Biotechnology & Genome ETF stock for Q1 2026, down 8.2% quarter-over-quarter.
  • 8 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2026 and 12 closed out, a net change of -4 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q1 2026 was Royal Bank of Canada, an estimated $987K added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q1 2026 was Q3 Asset Management, an estimated $1.43M sold.

Based on aggregated 13F filings for Q1 2026.